AU6620596A - Use of transglutaminase modulators to promote wound healing - Google Patents

Use of transglutaminase modulators to promote wound healing

Info

Publication number
AU6620596A
AU6620596A AU66205/96A AU6620596A AU6620596A AU 6620596 A AU6620596 A AU 6620596A AU 66205/96 A AU66205/96 A AU 66205/96A AU 6620596 A AU6620596 A AU 6620596A AU 6620596 A AU6620596 A AU 6620596A
Authority
AU
Australia
Prior art keywords
transglutaminase
modulators
wound healing
promote wound
promote
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66205/96A
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Publication of AU6620596A publication Critical patent/AU6620596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU66205/96A 1996-07-25 1996-07-25 Use of transglutaminase modulators to promote wound healing Abandoned AU6620596A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1996/001785 WO1998004245A1 (en) 1996-07-25 1996-07-25 Use of transglutaminase modulators to promote wound healing

Publications (1)

Publication Number Publication Date
AU6620596A true AU6620596A (en) 1998-02-20

Family

ID=10787759

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66205/96A Abandoned AU6620596A (en) 1996-07-25 1996-07-25 Use of transglutaminase modulators to promote wound healing

Country Status (2)

Country Link
AU (1) AU6620596A (en)
WO (1) WO1998004245A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012923B2 (en) * 1998-01-26 2000-02-28 新潟大学長 Drug for treating CAG repeat disease
WO1999065516A1 (en) * 1998-06-17 1999-12-23 Yeda Research And Development Co. Ltd. Methods and compositions for treating diseases mediated by transglutaminase activity
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
JP4755113B2 (en) * 2004-01-30 2011-08-24 クアーク・ファーマスーティカルス、インコーポレイテッド Oligoribonucleotides and methods of use thereof for the treatment of fibrotic conditions and other diseases
WO2006100679A2 (en) * 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
US8946201B2 (en) 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
KR20090028880A (en) * 2007-09-17 2009-03-20 재단법인서울대학교산학협력재단 Pharmaceutical compositions for preventing or treating fibrosis
WO2010033507A1 (en) * 2008-09-16 2010-03-25 St. Louis University Method of enhancing tgf-beta signalling
BRPI1009325A2 (en) * 2009-03-19 2016-03-08 Univ Queensland targets for growth factor signaling and therapy method
US20130236480A1 (en) * 2010-06-02 2013-09-12 Pierre-Louis Tharaux Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
CA3067905A1 (en) * 2017-06-23 2018-12-27 Vivier Canada Inc. Putrescine topical formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021440A (en) * 1989-07-31 1991-06-04 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5124358A (en) * 1990-01-16 1992-06-23 The Board Of Reagents The University Of Texas System Effect of transglutaminase inhibition on microfilariae development and macrofilariae viability
US5885982A (en) * 1992-03-23 1999-03-23 Dolynchuk; Kenneth Nicholis Use of transglutaminase inhibitor for the treatment of scar tissue
DE69328228T2 (en) * 1992-04-21 2000-12-21 Ajinomoto Co., Inc. Wound medication

Also Published As

Publication number Publication date
WO1998004245A1 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
HUP9902770A3 (en) Modulators of tissue regeneration
AU1957697A (en) Methods and compositions for the modulation of cell proliferation and wound healing
AU2557397A (en) Removal of tissue
AU5520998A (en) Reduction of hair growth
PL315627A1 (en) Modulators of anchoring protein functions
AU3599597A (en) Reduction of hair growth
AU5799098A (en) Preparation of gabapentin
AU7592998A (en) Modulators of tissue regeneration
ZA955010B (en) Enhanced crosslinking of natural tissues
AU9319798A (en) Reduction of hair growth
AU5730298A (en) Reduction of hair growth
AU2909597A (en) Use of hollow microcapsules
AU6620596A (en) Use of transglutaminase modulators to promote wound healing
AU5158298A (en) Use of phenylcyclopropylamines to stimulate tear secretion
AU7290898A (en) Preparation of fagopyritols and uses therefor
AU2557097A (en) Enhanced expression of transgenes
AU4306197A (en) Use of inhibitors of the activity of retinoic acid to promote healing
AU4672199A (en) Modulation of angiogenesis and wound healing
AU5427398A (en) Cytoperfusion of tissue specimens
AU3560595A (en) Preparation of cisapride
AU5487298A (en) Novel therapeutic application of pyrrole derivatives
AU4224096A (en) Use of phenylcyclohexylcarboxamides
AU1347799A (en) Hydrocolloid wound dressing and the method of making and using the same
AU2870597A (en) Treatment of liquid
AU1933297A (en) Manufacture of elongate members